Reviewnpj antimicrobials and resistance2025
Emerging antifungal resistance in Candida parapsilosis: the end of the innocence.
Review in npj antimicrobials and resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- First Isolation ofJournal of fungi (Basel, Switzerland) · 2026Article
- A trade-off between fungal biofilm formation and persistence in the host.PLoS biology · 2026Article
- Sporotrichoid lymphocutaneous infection caused byMedical mycology case reports · 2026Article
- A Retrospective Molecular Epidemiology Study: Emergence and dissemination of Azole-Resistant Candida parapsilosis Sensu Stricto in Southern Brazil.Mycopathologia · 2026Article
- First Case of Candidemia Caused by Fluconazole-Resistant Candida orthopsilosis Harboring the ERG11 G458S Mutation in a Hematopoietic Stem Cell Transplant Recipient in Asia.Mycopathologia · 2026Article
- Discovery of an Internal α-1,3-Linkage-Containing Manno-Oligosaccharide in theMicroorganisms · 2026Article
- Fpr1p mediates the synergistic effect of rapamycin or tacrolimus with caspofungin inJAC-antimicrobial resistance · 2026Article
- Candidemia in Türkiye demonstrates nationwide predominance of non-albicans Candida and Candida auris detection.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida parapsilosis is an opportunistic yeast that was recently deemed a high- importance fungal pathogen by the World Health Organization. In fact, C. parapsilosis poses an escalating threat in healthcare settings due to its ability to adapt to diverse environments, propensity for human-to-human transmission, and capacity to develop antifungal resistance. Recent studies emphasize its rising clinical importance, particularly with the increasing resistance to antifungals and the emergence of clonal outbreaks, making it a serious threat to public health. This review provides an up-to-date synthesis of our current knowledge on this yeast, addressing its epidemiology, environmental adaptability, and the molecular mechanisms driving resistance to azoles and echinocandins. In particular, it provides a comprehensive overview of the resistome of C. parapsilosis, offering insights into the genetic determinants associated with antifungal resistance. We also identify key unresolved questions and emphasize the need for further research to mitigate its impact on healthcare systems.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.